RetinalGenix Technologies Inc. (RTGN): R&D Expense

Annual figures by period end, from SEC filings.

$83.0K

Year ended 2025-12-31

$238.9K

Trailing 12 months to 2026-06-30

-28.1%

5-year compound annual growth

2020-12-31 R&D Expense (USD) 2025-12-31

Period ended	R&D Expense	Change YoY	Source filing
2025-12-31	$83.0K	-77.8%	2026-04-15, From 2025-01-01
2024-12-31	$373.3K	-28.8%	2026-04-15, From 2024-01-01
2023-12-31	$524.2K	n/a	2025-03-31, From 2023-01-01
No annual figure between 2021-12-31 and 2023-12-31.
2021-12-31	$680.3K	+57.6%	2022-04-15, From 2021-01-01
2020-12-31	$431.6K	n/a	2022-04-15, From 2020-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	R&D Expense	Change YoY
RetinalGenix Technologies Inc. (RTGN)	2025-12-31	$83.0K	-77.8%
ALR Technologies SG Ltd. (ALRTF)	2025-12-31	$793.3K	-10.2%
Odyssey Health, Inc. (ODYY)	2025-07-31	$0	-100.0%
Global Innovative Platforms Inc. (GIPL)	2025-09-30	$382.8K	n/m
Sigyn Therapeutics, Inc. (SIGY)	2024-12-31	$773.3K	-3.1%
Vycor Medical Inc (VYCO)	2025-12-31	$10.0K	-35.0%
Vivos Inc (RDGL)	2025-12-31	$352.2K	+8.5%
QHSLab, Inc. (USAQ)	2025-12-31	$484.9K	+64.7%
Harvard Apparatus Regenerative Technology, Inc. (HRGN)	2025-12-31	$2.65M	+14.8%

Compare RTGN, ALRTF, ODYY, GIPL side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗